Trials / Completed
CompletedNCT06488027
DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- AB Biotek · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the nervous system, among others. In this study we wanted to study the prevalence of DAO deficiency in pacients with insomnia symptoms.
Conditions
Timeline
- Start date
- 2023-05-05
- Primary completion
- 2023-11-27
- Completion
- 2023-11-27
- First posted
- 2024-07-05
- Last updated
- 2025-05-30
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT06488027. Inclusion in this directory is not an endorsement.